Evidence map›Paper›PMID 39409097›Full record

ReviewInternational journal of molecular sciences2024

Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder.

Sean Massey, Anita Quigley, Simone Rochfort, John Christodoulou, Nicole J Van Bergen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Epilepsy grand challenge 2025.Frontiers in neurology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sean MasseyBrain and Mitochondrial Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC 3052, Australia.
Anita QuigleyElectrical and Biomedical Engineering, School of Engineering, RMIT University, Melbourne, VIC 3000, Australia.
Simone RochfortSchool of Applied Systems Biology, La Trobe University, Bundoora, VIC 3083, Australia.ORCID 0000-0001-8442-6081
John ChristodoulouBrain and Mitochondrial Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC 3052, Australia.ORCID 0000-0002-8431-0641
Nicole J Van BergenBrain and Mitochondrial Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC 3052, Australia.ORCID 0000-0002-6768-3665

Funding

Minority Investigator Recruitment,Retention &CareersR13AG020106 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JACKSON, JAMES S · 2001 to 2001
$35k
CDKL5 Forum Junior Fellowship from the Loulou Foundation NAFoundation for Children Project Grant 2018-16Medical Research Future Funds (MRFF) Stem Cell Therapies Mission MRF2007465Million Dollar Bike Ride pilot grant from the Orphan Disease Center of the University of Pennsylvania MDBR-20-106-CDKL5Murdoch Children's Research Institute Near Miss grantMurdoch Children's Research Institute Strategic Pilot Project in Stem Cell and Genomic Medicine Research GrantMurdoch Children's Research Institute trategic Pilot Project in Stem Cell and Genomics MedicineRoyal Children's Hospital Foundation Chair in Genomic MedicineState Government of Victoria's Operational Infrastructure Support Program NAVESKI Near Miss Pilot Award
6 · The paper itself

Abstract

Pediatric genetic epilepsies, such as CDKL5 Deficiency Disorder (CDD), are severely debilitating, with early-onset seizures occurring more than ten times daily in extreme cases. Existing antiseizure drugs frequently prove ineffective, which significantly impacts child development and diminishes the quality of life for patients and caregivers. The relaxation of cannabis legislation has increased research into potential therapeutic properties of phytocannabinoids such as cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). CBD's antiseizure properties have shown promise, particularly in treating drug-resistant genetic epilepsies associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous Sclerosis Complex (TSC). However, specific research on CDD remains limited. Much of the current evidence relies on anecdotal reports of artisanal products lacking accurate data on cannabinoid composition. Utilizing model systems like patient-derived iPSC neurons and brain organoids allows precise dosing and comprehensive exploration of cannabinoids' pharmacodynamics. This review explores the potential of CBD, THC, and other trace cannabinoids in treating CDD and focusing on clinical trials and preclinical models to elucidate the cannabinoid's potential mechanisms of action in disrupted CDD pathways and strengthen the case for further research into their potential as anti-epileptic drugs for CDD. This review offers an updated perspective on cannabinoid's therapeutic potential for CDD.

Indexed as

CannabinoidsEpileptic SyndromesSpasms, InfantileAnimalsAnticonvulsantsCannabidiolDisease Models, AnimalEpilepsyHumansLennox Gastaut SyndromeProtein Serine-Threonine KinasesAnticonvulsantsCannabidiolCannabinoidsCDKL5 protein, humanProtein Serine-Threonine KinasescannabidiolcannabinoidsCBDCDDCDKL5refractory epilepsy

Identifiers

PMID39409097
PMCPMC11476665

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.